{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination significantly broadens the repertoire of tumor antigens presented by MHC-I molecules.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "The increased antigen presentation is linked to type I interferon signaling, which can be experimentally blocked, eliminating the benefit."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination sensitizes previously non-responsive tumors to the therapeutic effects of immune checkpoint blockade (ICI).",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.",
          "line_ref": "L36"
        }
      ],
      "caveat": "The observed human benefit comes from a retrospective, non-randomized cohort analysis, meaning residual confounding cannot be ruled out and direct causal interpretation is limited."
    },
    {
      "claim_id": "C03",
      "claim": "The sensitization effect is mechanistically dependent on the induction of Type I interferon signaling within the tumor microenvironment.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "The study noted that lipid particle controls lacking the mRNA sequence failed to reproduce the sensitization, indicating the payload is essential for this pathway activation."
    },
    {
      "claim_id": "C04",
      "claim": "The combined therapy increases tumor targetability by upregulating PD-L1 expression and enhancing CD8+ T-cell infiltration in the tumor.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        }
      ],
      "caveat": "Despite these favorable changes, ICI-only treatment still showed limited activity in low-immunogenic settings, suggesting the combination effect is synergistic rather than purely additive."
    }
  ]
}